Advertisements

New Antibiotic Offers Hope for More Effective Lyme Disease Treatment

by Ella

Lyme disease, transmitted by deer ticks that feed on infected animals such as deer and rodents, affects nearly half a million people annually in the United States. Early antibiotic treatment is crucial to prevent severe chronic complications like heart issues, neurological problems, and arthritis. Yet, current treatments have limitations, and scientists are seeking better options.

Advertisements

Piperacillin: A Promising Alternative to Doxycycline

Researchers at Northwestern University have discovered that piperacillin, an antibiotic related to penicillin, effectively cured Lyme disease in mice at doses 100 times lower than doxycycline—the current standard treatment. Remarkably, at this low dose, piperacillin had minimal impact on the gut microbiome, preserving beneficial bacteria.

Advertisements

In contrast, doxycycline and other commonly used antibiotics often disrupt gut bacteria, causing unpleasant side effects. Additionally, doxycycline fails to help 10-20% of patients and is not approved for young children—who face the highest risk of tick exposure.

Advertisements

The Growing Need for Improved Treatments

With climate change extending tick seasons and increasing Lyme disease prevalence, more effective and targeted therapies are urgently needed.

Advertisements

“Broad-spectrum antibiotics kill bacteria effectively but often harm the microbiome,” explained Brandon L. Jutras, lead researcher and associate professor at Northwestern’s Feinberg School of Medicine. “The future of Lyme treatment lies in customized medicine, targeting specific Borrelia strains with precision drugs.”

How the Research Was Conducted

The research team screened nearly 500 drugs using molecular models to assess how antibiotics interact with Borrelia bacteria, the Lyme disease pathogen. Piperacillin stood out for its ability to interfere with Borrelia’s unique cell wall synthesis, halting bacterial growth and causing cell death without damaging beneficial microbes.

Historically, piperacillin is given with tazobactam (a beta-lactamase inhibitor) to combat bacteria that produce enzymes which inactivate the antibiotic. However, Lyme-causing Borrelia do not produce such enzymes. The study found that the antibiotic alone is sufficient and that adding tazobactam unnecessarily broadens antibacterial activity, harming the microbiome.

Potential for Prophylactic Use

Since piperacillin is already FDA-approved for pneumonia, the researchers suggest it could be repurposed as a single-dose injection following a known deer tick bite to prevent Lyme disease before symptoms appear.

Looking Ahead

Lyme disease prevention remains challenging without an approved human vaccine. Jutras hopes that this research will pave the way for better diagnostic tools and more targeted treatments to combat Lyme disease effectively.

You Might Be Interested In:

Advertisements
Advertisements

You May Also Like

Womenhealthdomain is a professional women's health portal website, the main columns include women's mental health, reproductive health, healthy diet, beauty, health status, knowledge and news.

【Contact us: [email protected]

[email protected]

Call: 18066312111

© 2023 Copyright Womenhealthdomain.com